Planet Labs vs 22nd Century Group Inc — how do they compare? Planet Labs trades at $16.65 (market cap $6.25B), while 22nd Century Group Inc trades at $0.84 (market cap $621.67K). The key difference: Planet Labs is far larger — about 10053.6× 22nd Century Group Inc's market cap, and Planet Labs is trading nearer its 52-week high, 22nd Century Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Planet Labs for 4 Days and 22nd Century Group Inc for 32 Days on average.
| PL | XXII | |
|---|---|---|
Market Cap | $6.25B | $621.67K |
Volume | 19,125,340 | 45,625 |
Sector | Industrials | Consumer Staples |
52-Week High | $51.40 | $483.00 |
52-Week Low | $11.16 | $0.80 |
Typical Hold Time | 4 Days | 32 Days |
Enterprise Value | $5.89B | -$3.69M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
22nd Century Group (XXII) trades at $0.89, down 0.94% today, with a bearish technical signal despite oversold RSI readings. The company shows severe financial stress with negative gross margins of -54.6% and net income margin of -76.01%, though valuation metrics appear low with P/S of 0.09 and P/B of 0.03. Recent news highlights regulatory progress in nicotine reduction initiatives and expanded retail distribution for VLN products.
While analyst consensus remains bullish with 75% buy ratings and a $1,240 price target, fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock presents high-risk speculation on regulatory adoption of reduced-nicotine standards, requiring careful risk assessment given the company's ongoing losses and cash burn.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Planet Labs operates Earth-imaging satellites and provides geospatial data products. Its imagery and analytics help governments and businesses monitor changes across the planet.
Read more on PL →22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →